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ABSTRACT
Background Advances in the understanding of complex trait genetics have always been enabled by advances
in genomic technology. Next-generation sequencing (NGS) is set to revolutionize the way complex trait genetics
research is carried out.
Results NGS has multiple applications in the ﬁeld of human genetics, but is accompanied by substantial study
design, analysis and interpretation challenges. This review discusses key aspects of study design considera-
tions, data handling issues and required analytical developments. We also highlight early successes in mapping
genetic traits using NGS.
Conclusion NGS opens the entire spectrum of genomic alterations for the genetic analysis of complex traits
and there are early publications illustrating its power. Continuing development in analytical tools will allow the
promise of NGS to be realized.
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Advances in complex trait genetics
The ﬁeld of complex trait genetics has progressed rapidly over
the last 5 years. Irreproducible candidate gene studies examin-
ing a few single nucleotide polymorphisms (SNPs) and declar-
ing signiﬁcance at relaxed thresholds riddled the literature and
represented standard study design and practice less than a
decade ago. Advances in high-throughput genotyping technol-
ogies revolutionized our understanding of human genome
variation, enabled better-designed studies and, with dropping
costs, ultimately enabled genome-wide association scans
(GWAS). GWAS transformed the ﬁeld of complex trait research
and have been very successful in identifying robustly associ-
ated common variants. The ﬁeld is now shifting towards the
study of lower frequency and rare variants, which have recently
been shown to inﬂuence common traits. These studies can only
be empowered by technological advances (in sequencing and
rare variant typing), improved bioinformatics approaches and a
better understanding of human sequence variation and thus
following the historical trend of advances in human genetics.
History of sequencing technology development
Sequencing technology advances are inextricably linked with
advances in chemistry, biology, engineering and computer
science [1,2]. The history of DNA sequencing has been charac-
terized by two periods of rapid development (1970–1977;
2005–2010) with 28 intervening years of gradual progress. In
December of 1977, Sanger et al. [3] published their ‘‘dideoxy
method’’ that used chain-terminating nucleotide analogues to
cause base-speciﬁc termination of primed DNA synthesis. This
eventually became the workhorse of DNA sequencing over the
next 28 years and was the foundation of the sequencing of the
human genome published in 2001 [4,5]. Developments between
1977 and 2005 (when the ﬁrst next-generation paper was pub-
lished) were centred on increasing throughput and accuracy
and decreasing cost. Important advances such as the invention
of PCR [6], the development of the ﬁrst automated DNA
sequencer [7] and of dye-terminator sequencing [8], the release
of commercial automated sequencers and the introduction of
capillary electrophoresis for separating DNA molecules [9,10]
paved the way for sequencing to play an important role in
expanding biological knowledge.
The need for high-throughput, low-cost sequencing drove
the development of massively parallel technologies, also
termed next-generation sequencing (NGS) technologies. The
ﬁrst generation of NGS technologies achieved this using
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SOLiD)[12]andsequencingbysynthesis(e.g.Illumina,Helicos)
[13–15].Costshavealreadydroppeddramaticallyfrom$500
Millionfortheﬁrsthumangenometo$10Millionusingcapil-
larysequencingto$30 000pergenomeusingNGSin2010.
NGS applications in complex trait research
Next-generation sequencing can be used both for de novo
sequencing of genomes (requiring sequence assembly) and for
sample re-sequencing that compares the resulting data to the
reference sequence to discover variation present in the sample.
NGS greatly expands the types, sizes and frequency spectra of
genomic variation amenable to analysis. In addition to genomic
variation, NGS is an ideal platform to investigate gene expres-
sion below the noise level of microarrays, analyse allele-speciﬁc
gene expression, investigate alternative splicing, histone modi-
ﬁcations, transcription factor binding and achieve methylome
analysis at base-pair resolution. Currently, the most widely
used application of NGS in complex trait genetic studies
involves SNP discovery and genotyping. NGS allows the previ-
ously unattainable, systematic discovery of low frequency vari-
ants in thousands of samples and association of these variants
with phenotypes of interest. NGS can also facilitate the detec-
tion and typing of structural variants along their full size and
frequency spectra, although the ﬁeld is still in its infancy (but
will undoubtedly rapidly progress). Large-scale experiments
such as the 1000 genomes (http://www.1000genomes.org/
page.php) and the UK10k (http://www.uk10k.org/) projects
will provide an excellent resource of sequence data and derive
variant information for the scientiﬁc community. As with the
advent of high-throughput genotyping a few years ago, NGS is
a technological advance that requires specialized analysis tools
and carries speciﬁc study design considerations that are just
now starting to be addressed.
Analytical challenges
Although NGS can open up vast opportunities for the discovery
of complex trait genetic determinants, several analytical chal-
lenges need to be addressed ﬁrst. We discuss ﬁve of these issues
that range from study design to downstream analyses below.
Optimizing parameters for sequencing study design
The advent of NGS has given rise to novel study design consid-
erations, beyond those encountered by researchers conducting
large-scale genotyping experiments. Theoretically, NGS can
deliver whole-genome sequencing (WGS) for individual
samples, but realistically a cost-to-data equilibrium has to be
reached within the context of the research question. This can be
balanced by considering only a fraction of the genome and⁄or
by pooling samples. Whole-genome, whole-exome and targeted
gene⁄region re-sequencing offer different levels of agnosticity
with inversely correlated costs. WGS approaches are appropri-
ate when there is no a priori biological reason to restrict the
investigation to speciﬁc regions of the genome. A similar
approach was followed in GWAS and conclusively showed that
common variants underlying complex traits are distributed
across the genome and are not preferentially situated within
genes. However, WGS can be prohibitively expensive. Whole-
exome sequencing offers coverage of exons and noncoding
RNAs and is the gene-centric global alternative to WGS.
Targeted regional re-sequencing can be useful in ﬁne-mapping
experiments, for example following identiﬁcation of robust
GWAS signals. Non-WGS approaches employ sequence enrich-
ment techniques (PCR, array-based sequence capture and
in-solution capture) focusing on regions of interest. Sequence
capture methods enable large-scale experiments that would not
be feasible with PCR (which is difﬁcult to multiplex, optimize
and normalize, but can be highly effective). Cost efﬁciency can
also be improved by pooling DNA samples rather than
sequencing samples individually. Pools can either be indexed
or nonindexed and the choice depends on the goal of the exper-
iment. Indexing pools allow the 1:1 mapping of reads to sam-
ples, whereas nonindexed pooling does not. Nonindexed pools
break the relationship between reads and samples and place an
enormous burden on variant calling algorithms to disentangle
true variants from NGS errors. Indexing allows individual
genotyping and increased frequency estimation accuracy. The
advent of NGS has also added considerations to the way in
which power is calculated, for example depth of coverage has
to be taken into account. Sample selection is another important
aspect of study design. Depending on the research question
asked, NGS experiments may be most powerful when focusing
on families, unrelated individuals, selected cases and controls
or individuals from the extremes of a trait distribution.
Storing and handling data
The ﬁrst pragmatic requirement of NGS analysis involves an
informatics infrastructure to store, access and handle these
data of unprecedented scale. Raw data from NGS platforms
are base incorporation ﬂuorescence images, analysis of
which produces the base calls. As an example, a single run
of an Illumina GAII sequencing machine produces approxi-
mately four terabytes (Tb) of data, but archiving of these
raw image ﬁles is no longer considered necessary. Sequence
alignment map (SAM) and the binary equivalent (BAM) ﬁle
formats are now routinely used in production pipelines [16]
across platforms. Compute and storage capacity are major
considerations in NGS data generation, and the ﬁeld is
debating migration towards cloud computing as a possible
solution.
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The ﬁrst step in analysing NGS data is mapping and alignment
(alignment for short) of the generated small reads to a reference
sequence. Computational challenges associated with this task
include handling the sheer number of reads, dealing with
nonunique mapping and variation in base quality, and have
required algorithm development to produce efﬁcient programs
for mapping NGS reads to the reference genome [17–23]. Li and
Homer [24] provide a detailed comparison of alignment algo-
rithms. Read alignment is a computationally intensive task, and
a bottleneck in the analysis of NGS data. Alignment algorithms
are evolving and becoming faster, which is a necessity as lane
throughput continues to grow. Correct read alignment to the
reference is an extremely important step, as any mapping errors
are then propagated into downstream analysis. A further major
determinant of alignment algorithm performance is the com-
pleteness and accuracy of the reference genome. The current
human reference genome is a composite genome from a small
set of individuals and contains gaps. Recent publications of
individuals’ entire genomes have revealed that they contain
sequence that is not found anywhere in the reference human
genome [14,15,25]. Recent unpublished work has shown an
improvement in overall alignment accuracy if this novel
sequence is included as part of the reference (DePristo and Li,
unpublished). Emerging whole-genome NGS data will allow
the construction of a more complete reference genome.
Variant calling and genotyping
The discovery and genotyping of sequence variants repre-
sents the cornerstone of NGS data use in complex trait
genetic association studies. There are several challenges in
calling true variants and distinguishing them from mapping
and sequencing errors. The ﬁeld has therefore been active in
developing and optimizing SNP (variant) calling algorithms.
We focus here on three of the sources of confounding that
can substantially complicate the identiﬁcation and genotyping
of variants from NGS data: (i) alignment artefacts around
small insertions–deletions (indels), (ii) PCR artefacts from
library preparation and (iii) error proﬁle of reads. Alignment
artefacts due to indels are a major source of false positive
SNP calls. The misalignment of reads containing small indels
is a consequence of the fact that all reads are mapped inde-
pendently and is exacerbated by algorithms that do not
perform gapped alignments (M. A. Depristo et al. in prepara-
tion). The consequences of such resulting misalignment are
that there will be several base mismatches with the reference
around the indel. These mismatches are errors but appear to
the variant calling algorithms as high-conﬁdence SNPs
because they are supported by multiple reads, all with poten-
tially good mapping quality scores (Figure 1). Therefore,
either SNP calling algorithms need to be indel-‘aware’ or
potential indels should ﬁrst be identiﬁed, local realignment
or assembly performed around them, followed by SNP
Reference sequence
Read suppor ng reference
Read suppor ng inser on
Misaligned read
False SNP calls
Misaligned read
Inser on
CAGCTGGAAATT**CCTTCTTTGAAGTC
CAGCTGGAAATT**CCTTCTTTGAAGTC
CAGCTGGAAATTGCCCTTCTTTGAAGTC
GC**CCTTCTTTGAAGTC
CAGCTGGAAATT**GCC
Figure 1 Consequences of Short Indel Misalignment on False Positive single nucleotide polymorphisms (SNP) Calling. Turquoise
bars represent false positive SNPs caused by the misalignment of reads containing a two base-pair insertion relative to the
reference. For the misaligned reads, since the inserted sequence occurs at the beginning⁄end of short reads, it is difﬁcult for the
alignment algorithms to recognize the insertion. Whereas for the correctly mapped insertion read, the inserted sequence occurs in
the middle of a read with perfect matches on either side of the indel allowing the alignment algorithm correctly open a gap in the
reference. Several SNPs in such a short window are hallmarks of indel misalignment.
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challenge to true variant discovery is a consequence of errors
introduced through the PCR steps in library preparation.
Sequencing experiments expect that each base is equally
likely to be covered and that each read represents a unique
piece of DNA. However, in actuality, these null assumptions
are not realized due to both variable GC content and PCR
artefacts. The construction of Illumina libraries requires PCR,
and during this process, a particular DNA fragment can
become clonally ampliﬁed and over-represented in the
library. This leads to a single piece of DNA generating a
large number of nonindependent reads covering the same
bases. If the PCR reaction introduces DNA replication errors,
there may be numerous reads (depending on the cycle where
the error was introduced) supporting the correct and the
erroneous bases, thus generating what looks like a conﬁdent
SNP call. The use of paired-end sequencing libraries allows
researchers to identify and properly deal with these PCR-
related issues. The probability that two reads from a pair-end
library have the exact same outer coordinates is extremely
small; therefore, reads that have exactly the same outer coor-
dinates are considerably more likely to be clonal and nonin-
dependent. Currently, the recommended way to deal with
these reads is to mark them as duplicates, and only use the
read in the set with the best mapping quality. In this way, if
there truly is a variant at the locus, the evidence will come
from independent reads. The ﬁnal challenge in making good
SNP calls we discuss here is the location of the variant in the
reads that harbour the variant. Bases at the ends of reads can
have a substantially higher error rate than bases at the begin-
ning and middle of reads. SNP calling algorithms do consider
the base quality score, but it has been shown that quality
scores coming off the machines are not well-calibrated [M. A.
Depristo et al. in preparation, 26,27]. This makes recalibrating
the quality scores of the aligned bases before SNP calling
extremely important. Even with recalibrated base qualities,
the ends of reads can lead to spurious SNP calls. The
approach used to ﬁlter out spurious SNP calls due to base
calling errors involves clipping the end of reads, so that only
the portion of reads with high-conﬁdence bases is used for
alignment and variant calling. The road to high-conﬁdence
genotyping is paved with similar challenges. Until uncer-
tainty is minimized or eradicated, it is important to generate
variant-associated quality metrics that reﬂect the level of con-
ﬁdence both at the variantlevelandattheindividualgenotype
level(M.A.Depristoetal.inpreparation).
Analysing multiple low frequency and rare variants
with respect to the trait of interest
The search for causal loci in rare diseases with Mendelian
characteristics is conceivably relatively straightforward given
full sequence data, even though analyses will need to account
for sequence and calling errors that may give rise to false
positive or false negative ﬁndings in the case and control
samples studied. Detecting robust association with common,
complex traits can be a much more complicated analytical
task, as the effects sought can be very subtle. Single-point
analysis of low frequency and rare variants will require hun-
dreds of thousands of individuals in order to robustly detect
modest effect sizes. To overcome this issue, powerful
approaches for the aggregate analysis of multiple low fre-
quency⁄rare variants across a locus that may exhibit allelic
heterogeneity have recently started to emerge [28–30]
(Figure 2). Analogous methods incorporating sequence-
derived quality scores and genotype-speciﬁc uncertainty will
also be required in order to appropriately account for possi-
ble sources of error. The interpretation of signals from such
locus-wide approaches can be difﬁcult. The paradigm of
replication of association at the same variant, with the same
allele, in the same direction is starting to shift in order to
allow for heterogeneity across sample sets. Similarly, the
combination of data in meta-analytical frameworks will have
to accommodate conceivable differences in both effect size
and direction of effect across strata.
Individual 1
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Individual 8
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Figure 2 Graphical representation of allelic heterogeneity at a
locus with common and low frequency⁄rare variant associa-
tions with a complex trait. Turquoise bars represent trait-
related variants carried by different individuals at a locus of
interest. Bar width represents variant frequency (wider bars
denote variants with higher frequency). Single-point associa-
tion analysis of the low frequency⁄rare variants has extremely
low power, but composite analysis by considering all variants
of interest locus-wide is a more powerful alternative.
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Research published over the last 6 months has validated the
power of NGS to identify disease genes [31–35]. Different study
designs and different platforms have been employed to suc-
cessfully identify Mendelian disease loci, thus illustrating the
robustness of data generated by NGS. Choi et al. reported the
ﬁrst use of NGS to elucidate the genetic cause of a disease
through targeted re-sequencing of the exome of a single
individual using NimbleGen exon-capture arrays followed by
sequencing with Illumina’s Genome Analyzer platform [31].
Choi et al. found a homozygous missense mutation in SLC26A3
leading to a diagnosis of congenital chloride diarrhoea,
although the patient was originally suspected of having Bartter
syndrome. Ng et al. conducted a proof-of-concept experiment
using Agilent exon-capture arrays and Illumina’s Genome
Analyzer to sequence the exomes of four unrelated individuals
affected with the rare, dominantly inherited Freeman-Sheldon
syndrome (FSS) and eight unaffected HapMap individuals, and
unambiguously detected the previously identiﬁed gene MYH3
responsible for FSS [32]. Ng et al. followed this proof-of-concept
experiment with a study that identiﬁed mutations in the gene
DHODH as the previously unidentiﬁed cause of Miller
syndrome, a rare Mendelian disease. Lupski et al. used the
SoLID NGS platform to sequence the whole genome of an indi-
vidual with Charcot-Marie-Tooth neuropathy to identify the
causative alleles in the gene SH3TC2 and conﬁrmed the causa-
tive nature of the identiﬁed mutations by directly sequencing
the exons where the mutations occurred in all family members
[34]. Roach et al. sequenced a nuclear family with two siblings
affected by the recessive disorders Miller syndrome and
primary ciliary dyskinesia using Complete Genomics’ service-
based NGS [35] and was able to narrow down the disease-caus-
ing gene interval substantially. These ﬁve studies illustrate the
power of NGS to quickly identify the causes of rare, Mendelian
diseases by sequencing a small number of individuals. These
are promising ﬁrst steps in the use of NGS to identify disease
genes, but are very different in nature and scale from the
studies needed to identify susceptibility variants involved in
common, complex traits.
Sequencing strategies for complex trait locus identiﬁcation
can differ widely and come with different sensitivity and speci-
ﬁcity requirements (Table 1). Type 1 diabetes, a complex auto-
immune disease, has provided the ﬁrst example of NGS-driven
disease locus identiﬁcation. Nejentsev et al. identiﬁed four sig-
niﬁcantly associated low frequency⁄rare SNPs (MAF < 3%) in
IFIH1 by pooled re-sequencing of 480 cases and 480 controls
using the 454 platform and thus identiﬁed IFIH1 as the most
likely causative gene in the previously associated linkage
disequilibrium block that contained three other genes [36]. NGS
approaches are also shedding new light into the genomic events
underlying cancer. NGS of cancer genomes allows researchers
to identify both SNPs and genomic rearrangements on a
genome-wide scale, allowing for a greater understanding of
somatic mutations. For example, NGS has provided new
insight into recurrent mutations in acute myeloid leukaemia
[37], acquired somatic mutations in melanoma [38], substitu-
tions and rearrangements in lung cancer [39,40] and the evolu-
tion of substitutions and rearrangements found in breast cancer
[41,42]. These early applications demonstrate the potential of
NGS to help elucidate the genetics of diverse traits and
diseases.
Table 1 Sensitivity and speciﬁcity of next-generation sequencing designs in complex disease studies
Project type Example setting Sequencing design
Required
sensitivity
Required
speciﬁcity
Sequence variant
discovery
Variant identiﬁcation in candidate region
before genotyping follow-up
Targeted (nonindexed pools can
increase cost efﬁciency)
High Low
Novel association
discovery
Genome-wide sequence-based association
study; promising variants followed-up
with genotyping
Whole-genome⁄Whole-exome High Medium
Fine-mapping
established
association signal
Variant identiﬁcation and association
testing to narrow established association
signal
Targeted (indexed pools can
increase cost efﬁciency)
Medium High
Cancer somatic
mutation
Identifying interchromosomal
rearrangements, duplications,
ampliﬁcations, point mutations
Whole-genome (both normal and
cancer samples sequenced)
High High
Sensitivity is deﬁned as the ability to detect all variants present (e.g. high sensitivity ‡ high true positive rate). Speciﬁcity is deﬁned as the correctness of called
variants (e.g. high speciﬁcity ‡ high true negative rate).
European Journal of Clinical Investigation Vol 41 565
NEXT-GENERATION SEQUENCING AND COMPLEX TRAIT RESEARCHConclusions
Next-generation sequencing has, like many technological leaps
forward, realized numerous possibilities for the ﬁeld of com-
plex trait genetics. Although multiple production, study design,
analysis and interpretation issues remain unresolved, progress
in developing, calibrating and optimizing tools for more accu-
rate data delivery and powerful association analysis has started
to materialize. The gap in heritability left by the study of com-
mon variants can now be probed. Examples of successes are
starting to emerge in the literature [36]. NGS may hold the key
to linking sequence polymorphism along the full variation,
frequency and effect size spectrum to polygenic phenotypes
and is set to transform the way in which complex trait genetics
research is carried out.
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